keyword
MENU ▼
Read by QxMD icon Read
search

anti-tnf

keyword
https://www.readbyqxmd.com/read/29676289/natural-history-and-outcome-of-inflammatory-bowel-diseases-in-children-in-saudi-arabia-a-single-center-experience
#1
Khalid M Alreheili, Khalid A Alsaleem, Ali I Almehaidib
Background/Aim: Inflammatory bowel disease (IBD) is a chronic gastrointestinal disorder which includes ulcerative colitis (UC), Crohn's disease (CD), and indeterminate colitis (IC). The natural history of pediatric IBDs is poorly understood and generally unpredictable. We aim to study the natural history of IBD in Saudi children including the extraintestinal manifestations, changes in diagnosis, disease behavior, medical management, and surgical outcome. Patients and Methods: A retrospective review of all the charts of children less than 14 years of age who were diagnosed as IBD and followed up in King Faisal Specialist Hospital and Research Center (KFSH and RC) from January 2001 to December 2011 was performed...
April 18, 2018: Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association
https://www.readbyqxmd.com/read/29671663/a-note-on-improvement-in-dermatology-life-quality-index-dlqi-among-patients-with-hidradenitis-suppurativa-treated-with-adalimumab
#2
Simon Francis Thomsen
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with profound negative impact on quality of life. Adalimumab (anti-TNF) is indicated for moderate-to-severe HS unresponsive to conventional therapy. Herein, studies of the change in Dermatology Life Quality Index (DLQI) among patients with HS treated with adalimumab are reviewed. The anticipated gain in DLQI is only modest in patients with HS treated with adalimumab, even in trials of high quality, and does not exceed the established minimal clinically important difference...
April 19, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29671190/predictors-of-sustained-clinical-response-in-patients-with-beh%C3%A3-et-s-disease-related-uveitis-treated-with-infliximab-and-adalimumab
#3
Claudia Fabiani, Antonio Vitale, Donato Rigante, Giacomo Emmi, Giuseppe Lopalco, Jurgen Sota, Lorenzo Vannozzi, Gerardo di Scala, Silvana Guerriero, Ida Orlando, Rossella Franceschini, Marco Capozzoli, Bruno Frediani, Mauro Galeazzi, Florenzo Iannone, Gian Marco Tosi, Luca Cantarini
To identify clinical variables capable of predicting long-term treatment duration of TNF-α inhibition in patients with Behçet's disease (BD)-related uveitis. Demographic, clinical, and therapeutic data were retrospectively collected from BD patients treated with the tumor necrosis factor (TNF)-α blockers infliximab and adalimumab. Patients still continuing TNF-α inhibitors at 48-month follow-up visits were classified as long-term responders and were statistically compared to patients discontinuing treatment before the 48-month visit...
April 18, 2018: Clinical Rheumatology
https://www.readbyqxmd.com/read/29670622/immune-reconstitution-after-autologous-hematopoietic-stem-cell-transplantation-in-crohn-s-disease-current-status-and-future-directions-a-review-on-behalf-of-the-ebmt-autoimmune-diseases-working-party-and-the-autologous-stem-cell-transplantation-in-refractory
#4
REVIEW
Alan Graham Pockley, James O Lindsay, Gemma A Foulds, Sergio Rutella, John G Gribben, Tobias Alexander, John A Snowden
Patients with treatment refractory Crohn's disease (CD) suffer debilitating symptoms, poor quality of life, and reduced work productivity. Surgery to resect inflamed and fibrotic intestine may mandate creation of a stoma and is often declined by patients. Such patients continue to be exposed to medical therapy that is ineffective, often expensive and still associated with a burden of adverse effects. Over the last two decades, autologous hematopoietic stem cell transplantation (auto-HSCT) has emerged as a promising treatment option for patients with severe autoimmune diseases (ADs)...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29669052/cancer-associated-chemotherapy-induces-less-ibd-exacerbations-and-a-reduction-of-ibd-medication-afterwards
#5
Özgür M Koc, Roel J W van Kampen, Adriaan A van Bodegraven
Background: The prevalence of inflammatory bowel disease (IBD) is increasing and, consequently, more IBD patients will develop cancer with need for cancer-associated chemotherapy. Physicians are therefore confronted with whether they should continue, stop, or restart IBD medication in relation with chemotherapy. The current strategy in our hospital is to discontinue immunomodulating IBD medication, comprising corticosteroids, anti-tumour necrosis factor (anti-TNF), and other immunosuppressives, before starting chemotherapy...
April 13, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29668916/extraintestinal-manifestations-in-vedolizumab-and-anti-tnf-treated-patients-with-inflammatory-bowel-disease
#6
Marla C Dubinsky, Raymond K Cross, William J Sandborn, Millie Long, Xue Song, Nianwen Shi, Yao Ding, Samantha Eichner, Brandee Pappalardo, Arijit Ganguli, Anthony Wang
Background: Extra-intestinal manifestations (EIMs) can impact morbidity in patients with inflammatory bowel diseases (IBD; Crohn's disease [CD] and ulcerative colitis [UC]). This study compared incidence rates of EIMs in patients with moderate to severe IBD receiving gut-selective vedolizumab (VDZ) vs those receiving systemic anti-tumor necrosis factor (anti-TNF) therapies. Methods: Adult IBD patients receiving VDZ or anti-TNFs were identified from the MarketScan claims database from September 28, 2012, through September 30, 2016...
April 13, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29668901/combining-anti-tnf-%C3%AE-and-vedolizumab-in-the-treatment-of-inflammatory-bowel-disease-a-case-series
#7
Lydia C T Buer, Marte L Høivik, David J Warren, Asle W Medhus, Bjørn A Moum
Background: Anti-tumor necrosis factor α (anti-TNF-α) is important in the treatment of inflammatory bowel disease, but some patients experience only a partial response. In these patients, a combination of anti-TNF-α and vedolizumab (VDZ) may act as a bridge until the full VDZ effect occurs. At present, clinical data on combination treatment with anti-TNF-α and VDZ are not available. The aim of this case series was to evaluate the safety and clinical response of combination therapy with anti-TNF-α and VDZ in clinical practice...
April 12, 2018: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/29668129/-tuberculosis-in-the-era-of-anti-tnf-alpha-therapy-why-does-the-risk-still-exist
#8
John-Leonardo Torres-Castiblanco, Jorge Alberto Carrillo, Daniel Hincapié-Urrego, Adriana Rojas-Villarraga
Rheumatoid arthritis is an autoimmune systemic disease characterized mainly by inflammatory compromise of diarthrodial joints. Multiple drug therapies have been developed to control the activity of rheumatoid arthritis, among them, the first line of disease-modifying antirheumatic drugs (DMARD), and novel drug therapies such as the anti-TNF alpha therapy, with satisfactory clinical outcomes.Despite this positive fact, the use of this therapy implies the risk of producing negative effects due to its mechanism of action, which has been associated with multiple infections, especially tuberculosis, making it necessary to use screen tests before resorting to this kind of drugs...
March 15, 2018: Biomédica: Revista del Instituto Nacional de Salud
https://www.readbyqxmd.com/read/29668128/tuberculosis-associated-with-tumor-necrosis-factor-%C3%AE-antagonists-case-description-and-analysis-of-reported-cases-in-colombia
#9
Leandro Galvis, Ángel Y Sánchez, Leonardo F Jurado, Martha I Murcia
Tumor necrosis factor-α (TNF-α) is an important fundamental cytokine during the immune response against cancer and infections such as tuberculosis. This molecule also plays a key pathogenic role in complex and difficult-to-treat diseases such as rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and ulcerative colitis. The treatment of these diseases frequently needs TNF-α antagonists, which has been related to an increased risk of developing tuberculosis, mycoses, and other severe infections...
March 15, 2018: Biomédica: Revista del Instituto Nacional de Salud
https://www.readbyqxmd.com/read/29667146/cost-effectiveness-analysis-of-crohn-s-disease-treatment-with-vedolizumab-and-ustekinumab-after-failure-of-tumor-necrosis-factor-%C3%AE-antagonist
#10
Przemysław Holko, Paweł Kawalec, Andrzej Pilc
OBJECTIVE: The aim was to evaluate the cost-effectiveness of Crohn's disease (CD) treatment with vedolizumab and ustekinumab after failure of therapy with tumor necrosis factor-α antagonists (anti-TNFs). METHODS: The Markov model incorporated the lifetime horizon, synthesis-based estimates of biologics' efficacy in relation to anti-TNF exposure, and administration of biologics reflecting clinical practice (e.g., sequence of biologics, retreatment, 12-month treatment)...
April 17, 2018: PharmacoEconomics
https://www.readbyqxmd.com/read/29666076/histoplasma-meets-crohn-s-disease-a-rare-case-of-new-onset-ascites
#11
Charles Robert Bosshardt, John Gnann, Nilesh Lodhia
A 53-year-old man with Crohn's disease treated with adalimumab was hospitalised with abdominal pain, fatigue, fever and chills. CT scan of the abdomen showed chronic thickening of the terminal ileum and cecum and new-onset ascites. Further studies revealed weakly positive urine and serum histoplasma antigen. Laparoscopy revealed metastatic caking of the omentum and abdominal wall; peritoneal biopsy demonstrated organisms morphologically consistent with Histoplasma capsulatum No dissemination outside of the peritoneal cavity was evident...
April 17, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29663266/hepatitis-b-virus-screening-and-reactivation-in-a-national-va-cohort-of-patients-with-inflammatory-bowel-disease-treated-with-tumor-necrosis-factor-antagonists
#12
Rajesh Shah, Edith Y Ho, Jennifer R Kramer, Peter Richardson, Shubhada Sansgiry, Hashem B El-Serag, Jason K Hou
BACKGROUND: Practice guidelines recommend screening for hepatitis B virus (HBV) infection prior to initiating treatment of inflammatory bowel disease (IBD) with anti-tumor necrosis factor (anti-TNF) therapy. However, the adherence to these screening guidelines and the clinical outcomes of HBV reactivation following anti-TNF use are not well known. METHODS: This is a retrospective cohort study using the Veterans Health Administration datasets for IBD patients with filled prescriptions for anti-TNFs from 2003 to 2011...
April 16, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29657880/pulmonary-aspergillosis-after-treatment-with-infliximab-in-still-s-disease-and-a-literature-review-of-still-s-disease-and-pulmonary-aspergillosis
#13
Emrah Şeyhoğlu, Abdülsamet Erden, Levent Kılıç, Ömer Karadağ, Sevtap Arıkan Akdağlı, Ali Akdoğan, Umut Kalyoncu
The use of anti-tumor necrosis factor alpha (anti-TNF-α) agents has increased during the past decade in rheumatology practice. Opportunistic infections have been reported with anti-TNF-α agents in clinical trials and post-marketing usage. Aspergillus infection is a rare opportunistic infection that is associated with immunosuppression, and there are reported cases of pulmonary aspergillosis in various rheumatic diseases treated with anti-TNF-α agents. Here, we present the first case of pulmonary aspergillosis associated with infliximab treatment in a patient with Still's disease...
March 2018: European Journal of Rheumatology
https://www.readbyqxmd.com/read/29657867/the-relationship-of-serum-endocan-levels-and-anti-tnf-alpha-therapy-in-patients-with-ankylosing-spondylitis
#14
Fatma Zehra Kadayıfçı, Makbule Gezmen Karadağ
Objective: Endocan is a marker for vascular pathogenesis and important mediator of angiogenesis that strongly associates with inflammation and vascular diseases. Growing evidence suggest that inflammatory cytokine tumor necrosis factor (TNF-alpha) plays a role in its regulation and secretion, whereas TNF-alpha inhibitors may have the opposite influence. The aim of this research is to investigate the association between serum endocan and anti-TNF-alpha drug treatment in patients with ankylosing spondylitis (AS)...
March 2018: European Journal of Rheumatology
https://www.readbyqxmd.com/read/29657833/paradoxical-arthritis-occurring-during-anti-tnf-in-patients-with-inflammatory-bowel-disease-histological-and-immunological-features-of-a-complex-synovitis
#15
Stefano Alivernini, Daniela Pugliese, Barbara Tolusso, Laura Bui, Luca Petricca, Luisa Guidi, Luisa Mirone, Gian Ludovico Rapaccini, Francesco Federico, Gianfranco Ferraccioli, Alessandro Armuzzi, Elisa Gremese
Objective: Paradoxical arthritis under tumour necrosis factor inhibitor (TNF-i) for inflammatory bowel disease (IBD) has been described. This study aims to evaluate the histological features of paired synovial tissue (ST) and colonic mucosa (CM) tissue in patients with IBD developing paradoxical arthritis under TNF-i. Methods: Patients with IBD without history of coexisting joint involvement who developed arthritis under TNF-i were enrolled. Each patient underwent ST biopsy and ileocolonoscopy with CM biopsies...
2018: RMD Open
https://www.readbyqxmd.com/read/29657832/predictive-value-of-serum-calprotectin-s100a8-a9-for-clinical-response-after-starting-or-tapering-anti-tnf-treatment-in-patients-with-rheumatoid-arthritis
#16
Lieke Tweehuysen, Nathan den Broeder, Noortje van Herwaarden, Leo A B Joosten, Peter L van Lent, Thomas Vogl, Frank H J van den Hoogen, Rogier M Thurlings, Alfons A den Broeder
Objectives: Calprotectin (S100A8/A9) has been correlated with disease activity in rheumatoid arthritis (RA). The aim of this study was to investigate the predictive value of serum calprotectin for clinical response after starting and tapering anti-tumour necrosis factor treatment in RA. Methods: Serum samples and clinical outcomes were derived from two longitudinal RA studies.At baseline (starting or tapering of adalimumab or etanercept), calprotectin levels were determined by ELISA...
2018: RMD Open
https://www.readbyqxmd.com/read/29657140/longterm-safety-and-efficacy-of-adalimumab-and-infliximab-for-uveitis-associated-with-juvenile-idiopathic-arthritis
#17
Vanessa Cecchin, Maria Elisabetta Zannin, Daniele Ferrari, Irene Pontikaki, Elisabetta Miserocchi, Maria P Paroli, Claudia Bracaglia, Denise Pires Marafon, Serena Pastore, Fulvio Parentin, Gabriele Simonini, Cinzia De Libero, Fernanda Falcini, Antonella Petaccia, Giovanni Filocamo, Riccardo De Marco, Francesco La Torre, Silvana Guerriero, Silvana Martino, Francesco Comacchio, Valentina Muratore, Giorgia Martini, Fabio Vittadello, Francesco Zulian
OBJECTIVE: Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated the safety and efficacy of adalimumab (ADA) and infliximab (IFX) for the treatment of JIA-associated uveitis in patients treated for ≥ 2 years. METHODS: Patients with JIA-associated uveitis treated with IFX and ADA were managed by a standardized protocol and data were entered in the ORCHIDEA registry. At baseline, all patients were refractory to standard immunosuppressive treatment or were corticosteroid-dependent...
April 15, 2018: Journal of Rheumatology
https://www.readbyqxmd.com/read/29655972/effectiveness-and-safety-of-anti-tnf-therapy-for-inflammatory-bowel-disease-in-liver-transplant-recipients-for-primary-sclerosing-cholangitis-a-nationwide-case-series
#18
Romain Altwegg, Roman Combes, David Laharie, Victor De Ledinghen, Sylvie Radenne, Filomena Conti, Olivier Chazouilleres, Christophe Duvoux, Jérôme Dumortier, Vincent Leroy, Xavier Treton, François Durand, Sébastien Dharancy, Maria Nachury, Félix Goutorbe, Géraldine Lamblin, Lucile Boivineau, Laurent Peyrin-Biroulet, Georges-Philippe Pageaux
BACKGROUND: There is a lack of consensus regarding the treatment of inflammatory bowel disease (IBD) after liver transplantation (LT) forprimary sclerosing cholangitis (PSC). AIM: To investigate the safety and effectiveness of anti-TNF therapy in patients with IBD after a LT for PSC. METHODS: We reviewed the medical files of all of the IBD patients who underwent a LT for PSC and who were treated with anti-TNF therapy at 23 French liver transplantation centers between 1989 and 2012...
March 13, 2018: Digestive and Liver Disease
https://www.readbyqxmd.com/read/29655835/risk-of-serious-and-opportunistic-infections-associated-with-treatment-of-inflammatory-bowel-diseases
#19
Julien Kirchgesner, Magali Lemaitre, Fabrice Carrat, Mahmoud Zureik, Md Franck Carbonnel, Rosemary Dray-Spira
BACKGROUND & AIMS: The risk of infection associated with tumor necrosis factor antagonists (anti-TNF) and thiopurines (combination therapy) is uncertain. We assessed the risk of serious and opportunistic infections in patients with IBD treated with thiopurine monotherapy, anti-TNF monotherapy, or combination therapy in a large cohort of patients in France. METHODS: We performed a nationwide population-based study of patients (18 years or older) with a diagnosis of IBD in the French national health insurance database; we collected data from January 1, 2009 until December 31, 2014...
April 12, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29644739/editorial-monitoring-vedolizumab-trough-serum-concentration-in-inflammatory-bowel-disease-following-the-fate-of-anti-tnf-alpha-agents
#20
EDITORIAL
M Fragaki, K Karmiris
No abstract text is available yet for this article.
May 2018: Alimentary Pharmacology & Therapeutics
keyword
keyword
34737
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"